Consensus Sartorius Stedim Biotech OTC Markets

Equities

SDMHF

FR0013154002

Market Closed - OTC Markets Other stock markets 12:16:14 10/07/2024 am IST			5-day change	1st Jan Change
176.2 ^USD	+0.69%		0.00%	-33.19%

10/07	Markets Powered by Alternating Current
09/07	Mixed feelings

Evolution of the average Target Price on Sartorius Stedim Biotech

Price target over the last 5 years

History of analyst recommendation changes

79921922cd.SXYTdjiI2ND0MQSL7pd27EXbdzrOH4dZi2ggIX6C_mU.HCJWNU3GueimQTfK2qczmQfqAAKkevUv3jhGbCTYoSMEDCcEfO-qhr98PA~1786041d1cc81a3b02481ec80451c5e7

Analyst Recommendations on Sartorius Stedim Biotech

Oddo BHF Upgrades Sartorius Stedim Biotech to Outperform from Neutral, Lowers PT	04/07	MT
SARTORIUS STEDIM BIOTECH : Gets a Neutral rating from Barclays	27/06	ZD
SARTORIUS STEDIM BIOTECH : EPS cut (2023: -13.7%, 2024: -16.4%)	03/06
Sartorius sinks again towards year low	16/05	DP
SARTORIUS STEDIM BIOTECH : Barclays reaffirms its Neutral rating	23/04	ZD
Sartorius Stedim: in the red with brokerage comments	22/04	CF
UBS Cuts Sartorius Stedim Biotech PT, Maintains at Neutral	22/04	MT
SARTORIUS STEDIM BIOTECH : Q1 24: A few positives despite the top-line miss	22/04
SARTORIUS STEDIM : UBS reduces target price	22/04	CF
SARTORIUS STEDIM BIOTECH : Jefferies remains its Buy rating	12/03	ZD
SARTORIUS STEDIM BIOTECH : FY23: Updated mid-term outlook offers much-valued ‘certainty’	30/01
SARTORIUS STEDIM : UBS raises its target price	29/01	CF
Sartorius thwarted by 21-day line - despite HSBC recommendation	10/01	DP
JPMORGAN : Sartorius outlook likely to be share price driver	02/01	DP
SARTORIUS STEDIM BIOTECH : Opinion change, from Buy to Add	19/12
Sartorius continues to slide - low since April 2020	23/23/23	DP
Sartorius and subsidiary recover - JPMorgan praises biotech orders	19/23/19	DP
SARTORIUS STEDIM BIOTECH : Disappointing preliminary Q3 23 puts mid-term outlook in question	17/23/17
Profit warning weighs heavily on Sartorius and subsidiary Stedim	13/23/13	DP
SARTORIUS STEDIM BIOTECH : Jefferies reiterates its Buy rating	29/23/29	ZD
Chinese headwinds could be more severe than expected	22/23/22
SARTORIUS STEDIM BIOTECH : Jefferies gives a Buy rating	06/23/06	ZD
SARTORIUS STEDIM BIOTECH : Credit Suisse remains Neutral	11/23/11	ZD
SARTORIUS STEDIM BIOTECH : Opinion change, from Buy to Add	25/23/25
SARTORIUS STEDIM BIOTECH : Q2 23 weakness overshadowed by positive management commentary	21/23/21

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

173.4 EUR

Average target price

237.3 EUR

Spread / Average Target

+36.91%

High Price Target

360 EUR

Spread / Highest target

+107.67%

Low Price Target

178 EUR

Spread / Lowest Target

+2.68%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Sartorius Stedim Biotech

BARCLAYS	Charles Pitman
alphavalue	Virendra Chauhan
UBS
JEFFERIES	James Vane-Tempest
CREDIT SUISSE	Dominic Lunn
JPMORGAN	Richard Vosser
HSBC	Rajesh Kumar
BERENBERG	Odysseas Manesiotis

Ratings for Sartorius Stedim Biotech

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar